Dr. Florian Fleckenstein from Germany's largest university hospital, Charité University Berlin, to present clinical results from over 60 cases using Nexsphere-F™.
This clinical results were presented for the first time in Europe, demonstrating the safety and efficacy of the product. No post-embolization pain, long-term skin discoloration, or other side effects associated with non-degradable products were observed.
Additionally, a reduction in post-procedural pain was confirmed.
-
NEXT NEXTBIOMEDICAL Applies for FDA Breakthrough Device Designation for ‘Nexsphere-F™’.
2025/02/10